Drugs / Indoximod
Indoximod
also known as
1-methyl-D-tryptophan · Indoximod HCL (F2) · 1-methyl-D-tryptophan, Indoximod, D-1MT, 1-MT · 1-methyltryptophan, d- · D-1-methyltryptophan · D-1MT · Indoximod Freebase · Indoximod HCL F1 · +3 more
Small molecule targets IDO1 via inhibition
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03852446 | Mar 2018 | — | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05106296 | Feb 2022 → Mar 2028 expected | ependymoma, glioblastoma, medulloblastoma, primary brain neoplasm | Theodore S. Johnson | Recruiting | No outcome recorded |
| Phase 1 | NCT03372239 | Nov 2017 → Jan 2018 | — | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02835729 | Jul 2016 → Oct 2019 | acute myeloid leukemia | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02460367 | Jan 2016 → Jul 2017 | non-small cell lung carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02502708 | Oct 2015 → Dec 2019 | diffuse intrinsic pontine glioma, ependymoma, gliosarcoma, medulloblastoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01191216 | Sep 2010 → Aug 2013 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00739609 | Aug 2008 → Oct 2012 | breast cancer, lung cancer, malignant pancreatic neoplasm, melanoma | NewLink Genetics Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00567931 | Oct 2007 → Jul 2012 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT02077881 | Aug 2014 → Jan 2018 | pancreatic adenocarcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02073123 | Jul 2014 → Jan 2018 | metastatic melanoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02052648 | Mar 2014 → Apr 2018 | gliosarcoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01042535 | Dec 2009 → Dec 2014 | male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04049669 | Oct 2019 → Aug 2026 overdue | diffuse intrinsic pontine glioma, ependymoma, glioblastoma, medulloblastoma | Theodore S. Johnson | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03301636 | Dec 2017 → Oct 2019 | melanoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01792050 | Feb 2013 → Jul 2016 | breast cancer | NewLink Genetics Corporation | Completed | Missed primary |
| Phase 2 | NCT01560923 | Oct 2012 → Dec 2018 | metastatic prostate carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT01302821 Background | Jan 2013 → Dec 2014 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indoximod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01792050 ↗ |
| Known as | 1-methyl-D-tryptophan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302821 ↗ |
| Known as | 1-methyl-D-tryptophan, Indoximod, D-1MT, 1-MT | “1-methyl-D-tryptophan, Indoximod, D-1MT, 1-MT” NCT01792050 ↗ |
| Known as | 1-methyltryptophan, d- | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Known as | D-1-methyltryptophan | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Known as | D-1MT | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Known as | Indoximod Freebase | “Drug: Indoximod Freebase” NCT02835729 ↗ |
| Known as | Indoximod HCL (F2) | “Indoximod HCL (F2) tablets” NCT03852446 ↗1“Drug: Indoximod HCL F2” NCT02835729 ↗ |
| Known as | Indoximod HCL F1 | “Drug: Indoximod HCL F1” NCT02835729 ↗ |
| Known as | N-1-methyl-d-tryptophan | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Known as | NLG-8189 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Known as | NSC-721782 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571209 ↗ |
| Action | Inhibit | “1-methyl-d-tryptophan (1-MT), a competitive inhibitor of the enzyme indoleamine 2, 3-dioxygenase (IDO)” NCT00567931 ↗ |
| Modality | Small molecule | “in combination with indoximod, an orally administered small-molecule inhibitor of the IDO pathway.” PMID 37534996 ↗ Sep 2023 |
| Route | Oral | “Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28.” NCT00567931 ↗ |
| Target | IDO1 | “D-1MT, or any other substance targeting this enzymatic pathway indoleamine-(2,3)-dioxygenase (IDO)” NCT00739609 ↗ |